Moderna jumps as Q1 update reiterates 2026 outlook and spotlights international demand
MRNA•Moderna shares are rising after the company’s Q1 2026 update reinforced its 2026 outlook and highlighted stronger international demand. Investors also appear to be re-rating the stock after the recent earnings-driven selloff, with attention on cost cuts and upcoming May conference appearances.
1. What’s moving the stock today
Moderna (MRNA) is trading higher as investors continue to digest its early-May Q1 2026 results and business update, which reiterated the company’s 2026 framework and emphasized a shift toward a more balanced U.S./international revenue mix. The stock’s move also reflects a modest rebound after the immediate post-earnings volatility, with traders focusing on operational discipline and cost reductions rather than one-time items.
2. The key drivers investors are reacting to
The latest quarterly update underscored that Moderna is still targeting up to 10% revenue growth in 2026 and highlighted international strength as a central pillar of that outlook. Management also pointed to a lower cost trajectory (including a cash-cost target that has been featured as a major internal focus), helping support sentiment even as the company remains loss-making on a GAAP basis.
3. What comes next to watch
Near-term attention is shifting to Moderna’s scheduled May conference appearances, which can reset expectations if the company provides incremental color on commercial execution, pipeline timing, or launch readiness across respiratory and oncology programs. Investors will also watch whether the stock can hold gains as the market refocuses from “beat-and-reiterate” headlines to the pace of demand normalization and any pipeline catalysts discussed in public forums.
